New prognostic factors in resectable non-small cell lung cancer.
作者信息
Smit E F, Groen H J, Splinter T A, Ebels T, Postmus P E
机构信息
Department of Pulmonary Diseases, University Hospital Groningen, Netherlands.
出版信息
Thorax. 1996 Jun;51(6):638-46. doi: 10.1136/thx.51.6.638.
Abstract
摘要
相似文献
1
New prognostic factors in resectable non-small cell lung cancer.可切除非小细胞肺癌的新预后因素
Thorax. 1996 Jun;51(6):638-46. doi: 10.1136/thx.51.6.638.
2
Non-small cell lung cancer: clinical value of new biological predictors.
Lung Cancer. 1997 Jun;17 Suppl 1:S37-58. doi: 10.1016/s0169-5002(97)00639-9.
3
Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.多种分子标志物检测（p53、C-Ki-ras、c-erbB-2）可改善潜在可治愈性切除的非小细胞肺癌的预后评估。
Br J Cancer. 2000 Aug;83(4):473-9. doi: 10.1054/bjoc.2000.1287.
4
[Molecular abnormalities in lung cancer].
Nihon Rinsho. 2002 May;60 Suppl 5:73-7.
5
Genetic evolutionary staging of early non-small cell lung cancer: the P53 --> HER-2/NEU --> ras sequence.早期非小细胞肺癌的基因进化分期：P53→HER-2/NEU→ras序列
J Thorac Cardiovasc Surg. 1999 Aug;118(2):259-67. doi: 10.1016/S0022-5223(99)70216-3.
6
New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression.
Chest. 1995 Jul;108(1):246-54. doi: 10.1378/chest.108.1.246.
7
Do molecular markers predict survival in non-small-cell lung cancer?分子标志物能否预测非小细胞肺癌的生存率？
Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1093-7. doi: 10.1164/ajrccm.157.4.9707108.
8
[Topics on gene abnormality in endometrial cancer].
Nihon Rinsho. 2004 Oct;62 Suppl 10:259-63.
9
Cellular oncogenes and suppressor genes as prognostic markers in cancer.
Clin Biochem. 1993 Dec;26(6):439-47. doi: 10.1016/0009-9120(93)80007-h.
10
Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.手术切除的非小细胞肺癌患者的生存预测标志物
Clin Cancer Res. 2000 Mar;6(3):1125-34.
引用本文的文献
1
Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.中文译文：
博曼氏抑制素浓缩物和口腔白色病损：一项随机、2b 期试验。
Cancer Prev Res (Phila). 2013 May;6(5):410-8. doi: 10.1158/1940-6207.CAPR-13-0004.
2
Genetics and pulmonary medicine. 7. Somatic mutations in the development of lung cancer.遗传学与肺部医学。7. 肺癌发生中的体细胞突变。
Thorax. 1998 Nov;53(11):979-83. doi: 10.1136/thx.53.11.979.
本文引用的文献
1
Inhibitors of carbohydrate processing: A new class of anticancer agents.碳水化合物加工抑制剂：一类新型抗癌药物。
Clin Cancer Res. 1995 Sep;1(9):935-44.
2
3
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.p53 依赖性凋亡调节抗癌药物的细胞毒性。
Cell. 1993 Sep 24;74(6):957-67. doi: 10.1016/0092-8674(93)90719-7.
4
Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.K-ras基因突变对手术切除的非小细胞肺癌患者的预后影响
Oncogene. 1993 Sep;8(9):2407-12.
5
bcl-2 protein in non-small-cell lung carcinoma.非小细胞肺癌中的bcl-2蛋白
N Engl J Med. 1993 Sep 2;329(10):690-4. doi: 10.1056/NEJM199309023291003.
6
Prevention of metastasis by inhibition of the urokinase receptor.通过抑制尿激酶受体预防转移。
Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5021-5. doi: 10.1073/pnas.90.11.5021.
7
Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group.I期非小细胞肺癌完全切除患者接受环磷酰胺、阿霉素和顺铂辅助化疗。肺癌研究组。
J Natl Cancer Inst. 1993 Feb 17;85(4):299-306. doi: 10.1093/jnci/85.4.299.
8
Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer.原发性切除非小细胞肺癌中p53突变和3p缺失的预后意义
Cancer Res. 1993 Jan 1;53(1):1-4.
9
c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung.c-k-ras和p53突变在肺腺癌发生的早期就会出现。
Am J Pathol. 1994 Feb;144(2):303-9.
10
p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein.p53 依赖性 G1 期阻滞涉及与 pRB 相关的蛋白质，并被人乳头瘤病毒 16 E7 癌蛋白破坏。
Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5320-4. doi: 10.1073/pnas.91.12.5320.
Zotero 插件